### ü´Å Pulm/CC: Evaluation for Œ±1-Antitrypsin Deficiency in COPD

#### ‚úÖ True Statements
1. Chronic obstructive pulmonary disease (COPD) is diagnosed in the appropriate clinical context by a **post‚Äëbronchodilator FEV‚ÇÅ/FVC ratio <0.70**.  
2. Most cases of COPD are caused by exposure to **respiratory irritants** such as tobacco smoke.  
3. **Œ±1‚ÄëAntitrypsin deficiency** is an important and **treatable** cause of COPD.  
4. Basilar emphysema, associated liver disease, panniculitis, or a strong family history of emphysema may suggest Œ±1‚Äëantitrypsin deficiency, but **none are sufficiently sensitive to exclude the condition without testing**.  
5. **Measuring an Œ±1‚Äëantitrypsin level is recommended in all patients diagnosed with COPD.**  
6. Measurement of **diffusing capacity (Dlco)** may help determine disease severity in COPD but **is not required to diagnose COPD**.  
7. **Fractional exhaled nitric oxide (FeNO)** testing has **no role in the diagnosis of COPD**.  
8. **Polysomnography** is indicated to confirm **obstructive sleep apnea (OSA)** and is **not indicated** in patients with COPD who lack symptoms of sleep‚Äëdisordered breathing.  
9. **Key Point:** An **Œ±1‚Äëantitrypsin level** should be measured **in all patients with COPD** to evaluate for Œ±1‚Äëantitrypsin deficiency.  

#### üí¨ Extra(s)
1. Spirometry confirmation is required to establish COPD before considering disease modifiers such as Œ±1‚Äëantitrypsin deficiency.  
5. In a patient newly diagnosed with COPD, **Œ±1‚Äëantitrypsin measurement** is the **best next diagnostic step**.  

#### üìö Reference
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.

#### üè∑Ô∏è Tags
#Pulm/CC #COPD #Alpha1AntitrypsinDeficiency #Diagnosis #Spirometry #AmbulatoryCare

#### üÜî Question ID
PMMCQ24050

#### üïí Last Updated
June 2025

---

#### üìñ Related Text
MKSAP: Pulmonary Medicine, Airways Disease, Chronic Obstructive Pulmonary Disease, COPD Disease Assessment

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. COPD disease assessment entails determining **symptom severity** and **risk of acute exacerbation**.  
2. Validated symptom tools include the **COPD Assessment Test (CAT)**, **Modified Medical Research Council (mMRC) dyspnea scale**, **St. George‚Äôs Respiratory Questionnaire**, and the **Clinical COPD Questionnaire**.  
3. The **Clinical COPD Questionnaire** is also often used to **screen** patients for COPD symptoms.  
4. High risk for recurrent acute exacerbations is predicted by **FEV‚ÇÅ <50% of predicted**, **‚â•2 exacerbations in the prior year**, or **any hospitalization** for an acute exacerbation.  
5. A formal assessment of COPD severity can be performed using the **GOLD model**, which combines **symptom assessment (CAT or mMRC)** with **exacerbation history**.  
6. The **CAT total score ranges from 0 to 40**, with higher scores indicating greater symptom severity.  
7. The **degree of airflow obstruction** on spirometry and the **presence of comorbid conditions** are additional markers of disease severity.  
8. **Pulse oximetry at rest and with exertion** should be used to determine the need for **supplemental oxygen**.  
9. **Arterial blood gases** should be measured to assess for **hypercapnia** in patients with a low FEV‚ÇÅ, change in mental status, acute exacerbation, elevated serum bicarbonate, or oxygen saturation **<92%** on pulse oximetry.  
10. An **Œ±1‚Äëantitrypsin level should be obtained once** in all patients with COPD.  
11. A pattern of **basilar emphysema**, **liver disease**, **panniculitis**, or **strong family history** may suggest Œ±1‚Äëantitrypsin deficiency but **cannot rule it out without testing**.  

#### üí¨ Extra(s)
5. The GOLD model uses **both** symptom burden and exacerbation history to guide treatment categories.  
8. Oxygen assessment begins with **pulse oximetry** before considering arterial blood gases.  
10. **Œ±1‚ÄëAntitrypsin testing** is a **one‚Äëtime** evaluation in COPD.  

#### üè∑Ô∏è Related Text Tags
#Pulm/CC #COPD #DiseaseAssessment #GOLD #CAT #mMRC #Exacerbations #Alpha1Antitrypsin

---

#### üñºÔ∏è Supplemental Figure(s)
<!-- None -->

#### üîä Supplemental Video(s)
<!-- None -->

#### üóæ Supplemental HTML Table(s)

<!-- Table: COPD Assessment Test (CAT) -->
<table>
  <caption><strong>COPD Assessment Test (CAT)</strong></caption>
  <thead>
    <tr>
      <th>Item</th>
      <th>0</th>
      <th>5</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>I never cough / I cough all the time</td><td>0</td><td>5</td></tr>
    <tr><td>I have no phlegm (mucus) in my chest at all / My chest is completely full of phlegm (mucus)</td><td>0</td><td>5</td></tr>
    <tr><td>My chest does not feel tight at all / My chest feels very tight</td><td>0</td><td>5</td></tr>
    <tr><td>When I walk up a hill or one flight of stairs I am not breathless / I am very breathless</td><td>0</td><td>5</td></tr>
    <tr><td>I am not limited doing any activities at home / I am very limited doing activities at home</td><td>0</td><td>5</td></tr>
    <tr><td>I am confident leaving my home despite my lung condition / I am not at all confident</td><td>0</td><td>5</td></tr>
    <tr><td>I sleep soundly / I don't sleep soundly because of my lung condition</td><td>0</td><td>5</td></tr>
    <tr><td>I have lots of energy / I have no energy at all</td><td>0</td><td>5</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: COPD Assessment Test (CAT))
1. The CAT includes **eight items** assessing cough, phlegm, chest tightness, breathlessness, activity limitation, confidence leaving home, sleep, and energy.  
2. Each CAT item is scored **0‚Äì5**, with **higher scores reflecting worse symptoms**.  
3. The **total CAT score is 0‚Äì40**.  

#### üí¨ Optional Extra(s)
3. Higher **total** CAT scores represent greater overall symptom burden.  

---

<!-- Table: Classification of COPD Severity by GOLD Patient Category -->
<table>
  <caption><strong>Classification of COPD Severity by GOLD Patient Category</strong></caption>
  <thead>
    <tr>
      <th>Patient Category</th>
      <th>Characteristics</th>
      <th>Exacerbations Per Year</th>
      <th>CAT Score</th>
      <th>mMRC Score</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>A</td><td>Low risk, fewer symptoms</td><td>‚â§1, no hospitalization</td><td>&lt;10</td><td>0‚Äì1</td></tr>
    <tr><td>B</td><td>Low risk, more symptoms</td><td>‚â§1, no hospitalization</td><td>‚â•10</td><td>‚â•2</td></tr>
    <tr><td>E</td><td>High risk</td><td>‚â•2 or ‚â•1 with hospitalization</td><td>Any</td><td>Any</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Classification of COPD Severity by GOLD Patient Category)
1. **GOLD A**: low risk, fewer symptoms; **‚â§1 exacerbation/year without hospitalization**; **CAT <10**; **mMRC 0‚Äì1**.  
2. **GOLD B**: low risk, more symptoms; **‚â§1 exacerbation/year without hospitalization**; **CAT ‚â•10**; **mMRC ‚â•2**.  
3. **GOLD E**: high risk defined by **‚â•2 exacerbations/year or ‚â•1 with hospitalization**, with **any CAT** and **any mMRC**.  

#### üí¨ Optional Extra(s)
3. Category **E** replaces prior high‚Äërisk groupings and is driven by **exacerbation history**.  

---

<!-- Table: Modified Medical Research Council (mMRC) Dyspnea Scale -->
<table>
  <caption><strong>Modified Medical Research Council (mMRC) Dyspnea Scale</strong></caption>
  <thead>
    <tr>
      <th>Score</th>
      <th>Description of Dyspnea</th>
      <th>Severity</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>0</td><td>I only get breathless with strenuous exercise.</td><td>None</td></tr>
    <tr><td>1</td><td>I get short of breath when hurrying on level ground or walking up a slight hill.</td><td>Mild</td></tr>
    <tr><td>2</td><td>I walk slower than people of the same age on level ground because of breathlessness, or I have to stop for breath when walking at my own pace on level ground.</td><td>Moderate</td></tr>
    <tr><td>3</td><td>I stop for breath after walking approximately 100 m or after a few minutes on level ground.</td><td>Severe</td></tr>
    <tr><td>4</td><td>I am too breathless to leave the house or I am breathless when dressing or undressing.</td><td>Very severe</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: mMRC Dyspnea Scale)
1. The **mMRC scale ranges from 0 to 4**, with **higher scores indicating worse dyspnea**.  
2. **mMRC 0**: breathlessness only with strenuous exercise.  
3. **mMRC 4**: too breathless to leave the house or breathless when dressing/undressing.  

#### üí¨ Optional Extra(s)
1. The mMRC can be paired with **CAT** in the GOLD model for symptom stratification.  

---

<!-- Table: GOLD Grades and Severity of Airflow Obstruction in COPD -->
<table>
  <caption><strong>GOLD Grades and Severity of Airflow Obstruction in COPD</strong></caption>
  <thead>
    <tr>
      <th>Category</th>
      <th>Severity</th>
      <th>Spirometry</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>GOLD 1</td><td>Mild</td><td>FEV<sub>1</sub> ‚â•80% of predicted</td></tr>
    <tr><td>GOLD 2</td><td>Moderate</td><td>50% ‚â§ FEV<sub>1</sub> &lt;80% of predicted</td></tr>
    <tr><td>GOLD 3</td><td>Severe</td><td>30% ‚â§ FEV<sub>1</sub> &lt;50% of predicted</td></tr>
    <tr><td>GOLD 4</td><td>Very severe</td><td>FEV<sub>1</sub> &lt;30% predicted</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: GOLD Grades and Severity of Airflow Obstruction in COPD)
1. **GOLD 1 (mild)**: FEV‚ÇÅ **‚â•80%** of predicted.  
2. **GOLD 2 (moderate)**: **50‚Äì79%** of predicted.  
3. **GOLD 3 (severe)**: **30‚Äì49%** of predicted.  
4. **GOLD 4 (very severe)**: **<30%** of predicted.  

#### üí¨ Optional Extra(s)
2. GOLD **grades** are based on **post‚Äëbronchodilator FEV‚ÇÅ** among patients with **FEV‚ÇÅ/FVC <0.70**.  

---
